177 related articles for article (PubMed ID: 3018392)
1. Effects of neuropeptide Y (NPY) at the sympathetic neuroeffector junction. Can pre- and postjunctional receptors be distinguished?
Wahlestedt C; Håkanson R
Med Biol; 1986; 64(2-3):85-8. PubMed ID: 3018392
[TBL] [Abstract][Full Text] [Related]
2. Evidence for different pre-and post-junctional receptors for neuropeptide Y and related peptides.
Wahlestedt C; Yanaihara N; Håkanson R
Regul Pept; 1986 Feb; 13(3-4):307-18. PubMed ID: 3010387
[TBL] [Abstract][Full Text] [Related]
3. Comparative structural requirements of brain neuropeptide Y binding sites and vas deferens neuropeptide Y receptors.
Martel JC; Fournier A; St-Pierre S; Dumont Y; Forest M; Quirion R
Mol Pharmacol; 1990 Oct; 38(4):494-502. PubMed ID: 2172766
[TBL] [Abstract][Full Text] [Related]
4. Effects of antihypertensive drugs on sympathetic vascular control in relation to neuropeptide Y.
Lundberg JM; Pernow J; Franco-Cereceda A; Rudehill A
J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S51-68. PubMed ID: 2455193
[TBL] [Abstract][Full Text] [Related]
5. Effects of various neuropeptide Y/peptide YY fragments on electrically-evoked contractions of the rat vas deferens.
Grundemar L; Håkanson R
Br J Pharmacol; 1990 May; 100(1):190-2. PubMed ID: 2372659
[TBL] [Abstract][Full Text] [Related]
6. Neuropeptide Y modulates the vascular response to periarterial nerve stimulation primarily by a postjunctional action in the isolated perfused rat kidney.
Oellerich WF; Malik KU
J Pharmacol Exp Ther; 1993 Sep; 266(3):1321-9. PubMed ID: 8371140
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide Y (NPY) and peptide YY (PYY) effects in the epididymis of the guinea-pig: evidence of a pre-junctional PYY-selective receptor.
Haynes JM; Hill SJ; Selbie LA
Br J Pharmacol; 1997 Dec; 122(7):1530-6. PubMed ID: 9421306
[TBL] [Abstract][Full Text] [Related]
8. Neuropeptide Y receptor subtypes, Y1 and Y2.
Wahlestedt C; Grundemar L; Håkanson R; Heilig M; Shen GH; Zukowska-Grojec Z; Reis DJ
Ann N Y Acad Sci; 1990; 611():7-26. PubMed ID: 2174225
[TBL] [Abstract][Full Text] [Related]
9. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action.
Wahlestedt C; Edvinsson L; Ekblad E; Håkanson R
J Pharmacol Exp Ther; 1985 Sep; 234(3):735-41. PubMed ID: 3928874
[TBL] [Abstract][Full Text] [Related]
10. Effects of the neuropeptide Y Y2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo.
Malmström RE; Lundberg JN; Weitzberg E
Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):106-11. PubMed ID: 11819028
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological evaluation of 1229U91, a novel high-affinity and selective neuropeptide Y-Y1 receptor antagonist.
Hegde SS; Bonhaus DW; Stanley W; Eglen RM; Moy TM; Loeb M; Shetty SG; DeSouza A; Krstenansky J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1261-6. PubMed ID: 8531090
[TBL] [Abstract][Full Text] [Related]
12. Synergism between neuropeptide Y and norepinephrine highlights sympathetic cotransmission: studies in rat arterial mesenteric bed with neuropeptide Y, analogs, and BIBP 3226.
Cortés V; Donoso MV; Brown N; Fanjul R; López C; Fournier A; Huidobro-Toro JP
J Pharmacol Exp Ther; 1999 Jun; 289(3):1313-22. PubMed ID: 10336522
[TBL] [Abstract][Full Text] [Related]
13. Two novel related peptides, neuropeptide Y (NPY) and peptide YY (PYY) inhibit the contraction of the electrically stimulated mouse vas deferens.
Allen JM; Adrian TE; Tatemoto K; Polak JM; Hughes J; Bloom SR
Neuropeptides; 1982 Dec; 3(2):71-7. PubMed ID: 6186938
[No Abstract] [Full Text] [Related]
14. Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide.
Modin A
Acta Physiol Scand Suppl; 1994; 622():1-74. PubMed ID: 7524267
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of a selective peptide antagonist of neuropeptide Y vascular postsynaptic receptors.
Lew MJ; Murphy R; Angus JA
Br J Pharmacol; 1996 Apr; 117(8):1768-72. PubMed ID: 8732289
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of analogues of peptide YY with modified N-terminal regions: relationships of amphiphilic secondary structures and activity in rat vas deferens.
Minakata H; Iwashita T
Biopolymers; 1990 Jan; 29(1):61-7. PubMed ID: 2328293
[TBL] [Abstract][Full Text] [Related]
17. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells.
Grundemar L; Håkanson R
Br J Pharmacol; 1991 Dec; 104(4):776-8. PubMed ID: 1725763
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the contractile effect of neuropeptide Y in feline cerebral arteries.
Edvinsson L
Acta Physiol Scand; 1985 Sep; 125(1):33-41. PubMed ID: 2864784
[TBL] [Abstract][Full Text] [Related]
20. Functional effects and ligand binding of chimeric galanin-neuropeptide Y (NPY) peptides on NPY and galanin receptor types.
Kahl U; Langel U; Bartfai T; Grundemar L
Br J Pharmacol; 1994 Apr; 111(4):1129-34. PubMed ID: 7518295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
